Macrocure Ltd Company Profile (NASDAQ:MCUR)

About Macrocure Ltd (NASDAQ:MCUR)

Macrocure Ltd logoLeap Therapeutics Ltd, formerly Macrocure Ltd, is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure. CureXcell is in Phase III. Its CureXcell addresses each phase of healing in the impaired wound, including the production of growth factors and other biochemical factors involved in fibroblast activation, cell migration and extracellular matrix production, stimulating the body's natural healing process. Its delivery method of direct superficial injection into the chronic wound allows the precise delivery of the cells into the defective wound tissue where they can be effective.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MCUR
  • CUSIP: N/A
  • Web: www.macrocure.com
Average Prices:
  • 50 Day Moving Avg: $1.51
  • 200 Day Moving Avg: $1.54
  • 52 Week Range: $0.75 - $3.20
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.72
  • P/E Growth: 0.00
Profitability:
  • Return on Equity: -24.50%
  • Return on Assets: -22.85%
Debt:
  • Current Ratio: 44.95%
Misc:
  • Average Volume: 40,588 shs.
  • Beta: 0.62
 

Frequently Asked Questions for Macrocure Ltd (NASDAQ:MCUR)

What is Macrocure Ltd's stock symbol?

Macrocure Ltd trades on the NASDAQ under the ticker symbol "MCUR."

How were Macrocure Ltd's earnings last quarter?

Macrocure Ltd (NASDAQ:MCUR) announced its earnings results on Tuesday, November, 17th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.04. View Macrocure Ltd's Earnings History.

Where is Macrocure Ltd's stock going? Where will Macrocure Ltd's stock price be in 2017?

1 analysts have issued 1-year price targets for Macrocure Ltd's shares. Their forecasts range from $1.00 to $1.00. On average, they anticipate Macrocure Ltd's stock price to reach $1.00 in the next year. View Analyst Ratings for Macrocure Ltd.

Who are some of Macrocure Ltd's key competitors?

How do I buy Macrocure Ltd stock?

Shares of Macrocure Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Macrocure Ltd's stock price today?

One share of Macrocure Ltd stock can currently be purchased for approximately $1.51.


MarketBeat Community Rating for Macrocure Ltd (NASDAQ MCUR)
Community Ranking:  2.2 out of 5 ( )
Outperform Votes:  31 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  69
MarketBeat's community ratings are surveys of what our community members think about Macrocure Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Macrocure Ltd (NASDAQ:MCUR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating
Consensus Rating:Sell (Score: 1.00)
Consensus Price Target: $1.00 (33.77% downside)

Analysts' Ratings History for Macrocure Ltd (NASDAQ:MCUR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/18/2016Credit Suisse GroupDowngradeNeutral -> Underperform$1.00N/AView Rating Details
10/28/2015Jefferies Group LLCLower Price TargetHold$1.50N/AView Rating Details
8/20/2015Oppenheimer Holdings, Inc.DowngradeOutperform -> Market Perform$20.00N/AView Rating Details
8/20/2015NomuraDowngradeBuy -> Neutral$20.00 -> $6.00N/AView Rating Details
(Data available from 6/22/2015 forward)

Earnings

Earnings History for Macrocure Ltd (NASDAQ:MCUR)
Earnings by Quarter for Macrocure Ltd (NASDAQ:MCUR)
Earnings History by Quarter for Macrocure Ltd (NASDAQ MCUR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/17/2015Q3($0.36)($0.32)ViewN/AView Earnings Details
8/4/2015Q215($0.37)($0.37)ViewListenView Earnings Details
5/11/2015Q115($0.38)($0.38)$0.01 millionViewN/AView Earnings Details
3/17/2015Q414($0.28)($0.42)ViewN/AView Earnings Details
11/3/2014Q314($0.31)($0.70)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Macrocure Ltd (NASDAQ:MCUR)
Current Year EPS Consensus Estimate: $-0.32 EPS
Next Year EPS Consensus Estimate: $-0.32 EPS

Dividends

Dividend History for Macrocure Ltd (NASDAQ:MCUR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Macrocure Ltd (NASDAQ:MCUR)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Macrocure Ltd (NASDAQ:MCUR)
Latest Headlines for Macrocure Ltd (NASDAQ:MCUR)
Source:
DateHeadline
americanbankingnews.com logoMacrocure (MCUR) Given Coverage Optimism Rating of -0.03
www.americanbankingnews.com - May 1 at 4:52 PM
streetinsider.com logoMacrocure (MCUR) Completes Merger with Leap Therapeutics
www.streetinsider.com - January 23 at 11:46 PM
streetinsider.com logoMacrocure (MCUR) Completes Merger with Leap Therapeutics - StreetInsider.com
www.streetinsider.com - January 23 at 6:44 PM
us.rd.yahoo.com logoMacrocure and Leap Therapeutics Complete Merger
us.rd.yahoo.com - January 23 at 10:15 AM
finance.yahoo.com logoLeap Therapeutics and Macrocure Complete Merger Transaction
finance.yahoo.com - January 23 at 10:15 AM
streetinsider.com logoLeap Presents Biomarker Data from Study of DKN-01 Combo with Paclitaxel in Esophageal Cancer (MCUR) - StreetInsider.com
www.streetinsider.com - January 20 at 1:28 AM
us.rd.yahoo.com logoLeap Therapeutics Presents Biomarker Data from Clinical Study of DKN-01 in Combination with Paclitaxel in Esophageal Cancer
us.rd.yahoo.com - January 19 at 8:28 PM
us.rd.yahoo.com logo3:33 pm Macrocure: Leap Therapeutics reported updated clinical and biomarker data from an ongoing study of DKN-01 in patients with cancer of the esophagus and gastroesophageal junction
us.rd.yahoo.com - January 19 at 8:28 PM
prnewswire.com logoSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of The Board of Directors of ... - PR Newswire (press release)
www.prnewswire.com - December 1 at 6:26 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of The Board of Directors of Macrocure Ltd.- MCUR
finance.yahoo.com - November 29 at 2:57 PM
finance.yahoo.com logoMacrocure Announces New Date for Special General Meeting of Shareholders to Approve Merger With Leap Therapeutics
finance.yahoo.com - November 25 at 11:19 AM
finance.yahoo.com logo8:10 am Macrocure delayed the scheduled date for its previously-announced special general meeting of shareholders regarding Leap Therapeutics merger approval by one week
finance.yahoo.com - November 25 at 11:19 AM
businesswire.com logoLeap Therapeutics Presents Data from Phase 1 Study of GITR Agonist
www.businesswire.com - November 12 at 6:12 PM

Social

Chart

Macrocure Ltd (MCUR) Chart for Thursday, June, 22, 2017

This page was last updated on 6/22/2017 by MarketBeat.com Staff